This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug delivery			
Delivery of therapeutic small interfering RNA to tumor-associated immune cells	<p>Conjugates consisting of siRNA linked to a toll-like receptor (TLR) agonist could be useful for improving the antitumor response of immune cells in the tumor microenvironment. In tumor-bearing mice, a conjugate consisting of a TLR9 agonist and an siRNA targeting the immune suppressor gene <i>signal transducer and activator of transcription 3 (STAT3)</i> significantly reduced tumor growth compared with a conjugate composed of an agonist and control siRNA ($p < 0.001$). Next steps include additional preclinical studies of the conjugates.</p> <p>SciBX 2(36); doi:10.1038/scibx.2009.1390 Published online Sept. 17, 2009</p>	<p>Multiple patent applications filed covering use in multiple indications including cancer; available for licensing from the City of Hope Office of Technology Licensing Contact: Brian Clark, City of Hope, Duarte, Calif. phone: 626-256-8697 e-mail: bclark@coh.org</p>	<p>Kortylewski, M. <i>et al. Nat. Biotechnol.</i>; published online Sept. 13, 2009; doi:10.1038/nbt.1564 Contact: Hua Yu, Beckman Research Institute at City of Hope, Duarte, Calif. e-mail: hyu@coh.org</p>